Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10004349HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10015578HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10006128HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10016062HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10028498HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10028499HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10021267HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10028500HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10038364HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TVIS10040827HBVENSG00000171094.18protein_codingALKYesNo238B6D4Y2
Q9UM73
TCGA Plot Options
Drug Information
GeneALK
DrugBank IDDB12267
Drug NameBrigatinib
Target IDBE0000359
UniProt IDQ9UM73
Regulation Typeinhibitor
PubMed IDs23239810; 25888090; 28597393
CitationsCeccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C: Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13.@@Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D: Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015 Feb 27;8:17. doi: 10.1186/s13045-015-0122-8.@@Markham A: Brigatinib: First Global Approval. Drugs. 2017 Jul;77(10):1131-1135. doi: 10.1007/s40265-017-0776-3.
GroupsApproved; Investigational
Direct ClassificationPhenylpiperidines
SMILESCOC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1
Pathways
PharmGKBPA166163482
ChEMBLCHEMBL3545311